Health News Releases

  • Today April 19
March 22, 2024 11:00
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=53912461&newsitemid=20240319911372&lan=en-US&anchor=TSE%3A4502%2FNYSE%
Rendering of Merck's new Bioprocessing Production Center in Daejeon, South Korea
March 21, 2024 13:29
Merck Invests More than € 300 Million in New Life Science Production Site in Korea
Merck invests more than € 300 million into a new Bioprocessing Production Center in Daejeon, South Korea. The new site is the largest investment by Merck's Life Science business sector in Asia-Pacific
March 19, 2024 15:19
AMWC 2024: Galderma to Share New Data From Its Leading Injectable Aesthetic Portfolio
Galderma will present the latest updates from its broad portfolio of clinically-proven and holistic range of aesthetic treatments at the 22nd Aesthetic & Anti-Aging Medicine World Congress (AMWC) on M
March 19, 2024 14:55
Crown Bioscience Recognized Once Again as T+ Employer® for the Third Year in a Row
Crown Bioscience (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.crownbio.com%2F&esheet=53911141&newsitemid=20240318198586&lan=en-US&anchor=Crown+Bioscience&index=1&md5=2736454e
March 17, 2024 09:55
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr) as monoth
March 15, 2024 09:45
First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
The Max Foundation (Max), a global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive services to patients worldwide, BeiGene, a global
Evan L. Tzanis, COO and EVP Head of R&D, Neuraptive Therapeutics, Inc. (Photo: Business Wire)
March 14, 2024 11:20
Neuraptive Therapeutics, Inc. Announces Positive 24-Week Data for NTX-001 in the Phase 2 NEUROFUSE Study, Reinforcing Previously Announced Proof of Concept 12-Week Data
Neuraptive Therapeutics, Inc., a pioneer in nerve repair and regeneration, is proud to announce new 24-week data from the ongoing NEUROFUSE Study for NTX-001, further solidifying the product's status
March 14, 2024 10:04
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
Takeda (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2F&esheet=53909424&newsitemid=20240313160788&lan=en-US&anchor=Takeda&index=1&md5=6f3040795d635d91a3047b63610ac3
March 13, 2024 11:40
Beckman Coulter and Fujirebio Expand Partnership to Develop Patient-friendly, Blood-based Neurodegenerative Disease Diagnostics
Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing, today announced an expansion of their partnersh
9 Hospitals from Aster DM Healthcare network recognised (Graphic: AETOSWire)
March 12, 2024 13:45
Nine Hospitals from Aster DM Healthcare Recognized in Newsweek’s ‘World’s Best Hospitals 2024’ List
Aster DM Healthcare (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.asterdmhealthcare.com%2F&esheet=53907936&newsitemid=20240311202772&lan=en-US&anchor=Aster+DM+Healthcare&index
March 12, 2024 09:24
BIO KOREA 2024 Opens Registration for Business Partnering
BIO KOREA 2024 (https://www.biokorea.org/index.asp), jointly held by the Korea Health Industry Development Institute (https://www.khidi.or.kr/kps) (KHIDI, President: Cha Soon-do) and Chungcheongbuk-do
March 11, 2024 09:15
Galderma @ AAD 2024: New Data Demonstrate the Long-Term Efficacy of Nemolizumab in Prurigo Nodularis and Its Durability in Atopic Dermatitis
Galderma today announced new data demonstrating nemolizumab’s long-term and increasing efficacy on skin lesions and other symptoms in prurigo nodularis through to week 52 in the OLYMPIA LTE study.[1]
March 10, 2024 13:55
Kenai Therapeutics Announces $82 Million Series A Financing to Advance Next Generation Allogeneic Cell Therapies for Neurological Diseases
Kenai Therapeutics, a biotechnology company leveraging induced pluripotent stem cell (iPSC) technology to discover and develop a platform of allogeneic neuron replacement cell therapies for neurologic
Co-founder and CEO, Professor Claude Wischik (Photo: Business Wire)
March 08, 2024 09:40
Two Year Sustained Cognitive Benefits of Hydromethylthionine Mesylate (HMTM) Indicated by TauRx's LUCIDITY Trial
TauRx Pharmaceuticals Ltd., a global leader in tau-based research in Alzheimer’s disease (AD), presented the 24-month data from its Phase 3 LUCIDITY trial of hydromethylthionine mesylate (HMTM) at the
March 07, 2024 14:30
C₂N Diagnostics, LLC Announces Investment From Eisai Inc.
C₂N Diagnostics, LLC (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.c2n.com&esheet=53905942&newsitemid=20240306427979&lan=en-US&anchor=C%26%238322%3BN+Diagnostics%2C+LLC&index=1
March 06, 2024 10:30
BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)
Ben Crosbie, CEO of The DRIPBaR and Sarah Lomas, Founder and CEO of REVIV Global, announce their exc
March 03, 2024 15:05
Wellness Market Leaders Join Forces: The DRIPBaR Powered by REVIV
The DRIPBaR (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fthedripbar.com%2F&esheet=53903816&newsitemid=20240301173923&lan=en-US&anchor=The+DRIPBaR&index=1&md5=5d9842f73fed8bbd9a42
March 03, 2024 12:08
Technology Holdings Launches TH Healthcare & Life Sciences: Revolutionizing the Healthcare Investment Banking Landscape, leveraging over two decades of Healthcare Investment Banking transaction experience
Technology Holdings (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftechnologyholdings.com%2F&esheet=53901632&newsitemid=20240226928319&lan=en-US&anchor=Technology+Holdings&index=1&
February 29, 2024 15:36
Galderma Announces Record 2023 Net Sales of Over 4 B USD and Significant Core EBITDA Margin Expansion
Galderma: Delivered against full year guidance for another consecutive year with strong financial performance · Galderma achieved net sales of 4.082 B USD, up 8.5% year-on-year on a constant cur
February 29, 2024 15:25
Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas
Takeda (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2F&esheet=53901571&newsitemid=20240226565897&lan=en-US&anchor=Takeda&index=1&md5=66a3b376ad586d49f3651a4e8ba4fd
February 29, 2024 14:00
Medidata and Sanofi Vaccines Extend Collaboration to Improve Patient Centricity and Trial Efficiency
Medidata (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.medidata.com%2F&esheet=53892194&newsitemid=20240206439222&lan=en-US&anchor=Medidata&index=1&md5=ba87686335d43b4ad5753838
February 28, 2024 17:02
Galderma to Showcase Latest Updates From Its Broad, Innovative and Leading Dermatology Portfolio at the 2024 American Academy of Dermatology Annual Meeting
Galderma, the pure-play dermatology category leader, will be showcasing its latest clinical and educational efforts at the American Academy of Dermatology (AAD) Annual Meeting from March 8-12, 2024, h
February 28, 2024 12:05
ReNAgade Therapeutics Appoints Joe Bolen, Ph.D., Chief Science Innovation Officer
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Joe Bolen, Ph.D., an Executive Partner at MPM BioImpact, former Chief Scientific Officer at P
February 28, 2024 11:50
BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
BeiGene (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.beigene.com%2F&esheet=53900859&newsitemid=20240226047170&lan=en-US&anchor=BeiGene&index=1&md5=9fa7f0cbddab2bafa454d24c749
February 25, 2024 10:15
Celltrion presents new two-year data for subcutaneous infliximab (CT-P13 SC) in inflammatory bowel disease (IBD) at the 19th ECCO Congress
Celltrion today presented positive two-year results from the extended LIBERTY studies (LIBERTY-CD1 and LIBERTY-UC2) in patients with moderately to severely active Crohn’s disease (CD) and ulcerative c
25 per page50 per page75 per page100 per page